Skip to content

Sunday, January 24, 2021

Latest:

CABENUVA approved by the FDA as first long-acting HIV regimen
Sovicell Announces New Website Launch
Boehringer Ingelheim and Enara Bio join forces to develop new Cancer Immunotherapies
Baxter enters Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
Sanofi to purchase Kymab and add OX40L monoclonal antibody to its pipeline

Pharma Industry Review

Pharma Industry Review

Events
Companies
Resources
Sectors
DISEASES
Investment
- Stocks
Projects
COVID-19

CKD

Latest Regulatory Renal Diseases Vascular Diseases

AstraZeneca’s FARXIGA® gets designation for Chronic Kidney Disease

October 3, 2020October 4, 2020 Pharmaceutical Industry Editor cardiovascular, CKD, CV Renal & Metabolism (CVMD), T2D

AstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III

Please leave this field empty

DON’T MISS A THING

Be the first to receive the latest news from the pharma industry

We don’t spam! Read our Privacy Policy for more info.

Check your inbox or spam folder to confirm your subscription.

TRENDING STOCKS

Stocks by TradingView

Featured Company

FEATURED
SYNENTEC

Featured

Category: Drug Discovery and Laboratory Equipment

Automated High-throughput Cell Imaging Systems Details Products Downloads Videos Press Releases Contact Details SYNENTEC is a leading manufacturer of automated high-throughput cell imaging systems. The company provides cutting-edge customised imaging solutions for your specific needs in cell line development and scientific research. Custom cell line development imaging systemsOptimising cell line selection is an important step to accelerate a drug discovery Read more…

LATEST

Featured Infectious Diseases Regulatory

CABENUVA approved by the FDA as first long-acting HIV regimen

January 22, 2021January 23, 2021 Pharmaceutical Industry Editor

The U.S FDA has given the green light to Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for

Sovicell Announces New Website Launch

January 22, 2021January 22, 2021 Pharmaceutical Industry Editor

Deals DISEASES Drug Development Immunology Oncology R&D

Boehringer Ingelheim and Enara Bio join forces to develop new Cancer Immunotherapies

January 18, 2021January 22, 2021 Pharmaceutical Industry Editor

COVID-19 Latest Manufacturing

Baxter enters Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

January 14, 2021January 15, 2021 Pharmaceutical Industry Editor

Deals DISEASES Immunology

Sanofi to purchase Kymab and add OX40L monoclonal antibody to its pipeline

January 14, 2021January 14, 2021 Pharmaceutical Industry Editor

COVID-19 DISEASES Infectious Diseases Latest Regulatory

EC and UK authorise Moderna’s RNA-based COVID-19 Vaccine

January 9, 2021January 9, 2021 Pharmaceutical Industry Editor

COVID-19 DISEASES Immunology Infectious Diseases Latest Regulatory

UK approves AstraZeneca and Oxford University COVID-19 vaccine

December 30, 2020December 30, 2020 Pharmaceutical Industry Editor

COVID-19 DISEASES Infectious Diseases Latest Regulatory

European Union starts COVID-19 vaccination program

December 27, 2020January 22, 2021 Pharmaceutical Industry Editor

COVID-19 DISEASES Infectious Diseases Latest

UK could approve AstraZeneca’s COVID-19 vaccine as early as next week

December 27, 2020December 27, 2020 Pharmaceutical Industry Editor

High-Throughput Assay for Prediction of Plasma Protein Binding

December 27, 2020December 27, 2020 Pharmaceutical Industry Editor

Anti-Lamin B1 Antibody

December 27, 2020December 27, 2020 Pharmaceutical Industry Editor

COVID-19 DISEASES Infectious Diseases Latest Regulatory

Moderna’s COVID-19 vaccine approved by the FDA for emergency use

December 19, 2020December 27, 2020 Pharmaceutical Industry Editor

Featured Product

High-Throughput Assay for Prediction of Plasma Protein Binding

December 27, 2020December 27, 2020 Pharmaceutical Industry Editor

The 20 min high-throughput assay estimates the binding of drugs to human serum albumin (HSA) and a1-acid glycoprotein (AGP) to

About Us

Pharma Industry Review is here to provide you with the latest news, reviews and insights from the pharmaceutical industry so that you can take your business one step ahead.

About Us

Contact Us
Editorial Standards
Terms & Conditions
Privacy Policy
Users

Useful Links

Client Portal
Advertise
Presentation Portal
Sectors
Projects

Ads

Copyright © 2021 Pharma Industry Review. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.

);

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok Privacy policy